This symposium, sponsored by the CSIRO and Monash University, looks closely at the scientific evidence for and against aspirin use for the chemoprevention of cancer. By attending this symposium you will:
Hear Prof Peter Rothwell from Oxford University, UK and Prof Carlo Patrono from the Catholic University, Rome, Italy discuss their world leading research that identified the associations between aspirin consumption and reduced risk of cancer and the mechanisms of action by which aspirin may have its protective effects respectively.
Learn of the advantages and drawbacks of regular aspirin consumption, and how these impact on aspirin’s current and future use in cancer prevention and management.
Learn how aspirin use might be personalised for maximum benefit and least risk of side effects.
Learn how the Aspirin Reducing Events in the Elderly (ASPREE) clinical trial led by Monash University and the University of Minnesota, and its associated Healthy Aging Biobank developed under CSIRO’s Flagship Collaboration Clusters program, is providing critical information on the safety and efficacy of aspirin as a chemopreventive agent in the aged.
Understand the cost benefit analysis associated with aspirin-based cancer chemoprevention and its potential impact on Australia’s health economics.